New drug duo targets hard-to-treat HER2 cancers

NCT ID NCT07698587

Not yet recruiting Disease control Sponsor: Suzhou Biomissile Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study is testing a new drug called BM230 combined with a PD-1 inhibitor (a type of immunotherapy) in people with advanced solid tumors that are related to HER2. The goal is to find the best dose and see if the combination is safe and can shrink tumors. The trial includes several cancer types, such as colorectal, esophageal, and cervical cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BM230 and a PD-1 inhibitor
What this could lead to: If successful, this combination could offer a new treatment option for several types of advanced solid tumors that are HER2-related.
What could go wrong: This is an early-phase trial (Phase 1b/2) with a small number of participants, so the safety and effectiveness are not yet proven. There is a risk of side effects from the combination therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.